YO-2 treatment reduced melanoma proliferation in Mock and LRP1 OE expressing, but not LRP1 KD cells (Figure 2H,I) in vitro, and tumor growth in Mock and LRP1-OE tumors in vivo (Figure 2J,K). The gene discussed is LRP1; the disease is neoplasm.